Feed ROIV
RO

Roivant Sciences ROIV · NASDAQ

$34.70 +3.49% (+$1.17)

Market cap
$24.2B
Enterprise value
$23.1B
P/E
-
Forward P/E
-
PEG
-
P/S
3,215.6x
P/FCF
-
EV/EBITDA
-
ROIC
-38.8%
Gross margin
81.2%
Net margin
-3,534.9%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-
Beta
1.10
Free float
80.6%

About the company

Roivant Sciences (ROIV) is a biotechnology company specializing in the development and commercialization of innovative drugs and therapies. Utilizing advanced technologies and a strategic approach to research and development, Roivant Sciences focuses on rapidly bringing new treatment options to market. The company is known for its unique model and portfolio, which includes various therapeutic areas. Roivant Sciences is also engaged in partnerships with other organizations to accelerate healthcare innovations. Roivant Sciences (ROIV) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on innovation and research.

Sector

Healthcare

Industry

Biotechnology

CEO

Matthew Gline

Employees

721

Headquarters

London

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.